Company news

AstraZeneca PLC news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AstraZeneca: Where has all the cash gone?

June 5, 2019

Lynparza nearly doubled time patients lived with

June 3, 2019

Pooled analyses of the roxadustat global Phase III

May 10, 2019

Trastuzumab deruxtecan demonstrated clinically

May 8, 2019

Calquence PhIII ASCEND trial met primary endpoint

May 7, 2019

Qternmet XR approved in the US for type-2 diabetes

May 3, 2019

Lynparza receives positive EU CHMP opinion for 1st

April 29, 2019

AZN: Q1 2019 Results

April 26, 2019

Lynparza approved in EU for the treatment of germl

April 10, 2019

Global Pharmaceuticals: 2018 industry sales

April 9, 2019

Selumetinib gets Breakthrough Therapy Designation

April 1, 2019

Results of Placing

March 29, 2019

Proposed placing of new ordinary shares

March 29, 2019

AZ and Daiichi Sankyo enter collaboration in novel

March 29, 2019

Forxiga approved in Japan for type-1 diabetes

March 27, 2019

Forxiga approved in Europe for type-1 diabetes

March 25, 2019

US FDA grants saracatinib ODD for IPF

March 18, 2019

Lynparza receives positive EU CHMP opinion

March 1, 2019

Lynparza significantly delayed disease progression

February 26, 2019

Brilinta's PhIII THEMIS trial met primary endpoint

February 25, 2019

AstraZeneca Full-Year and Q4 2018 Results

February 14, 2019

US FDA grants Fasenra Orphan Drug Designation

February 6, 2019

US FDA grants Breakthrough Therapy Designation

February 5, 2019

EMA grants PRIME eligibility for MEDI8897

February 5, 2019

Forxiga receives positive EU CHMP opinion

February 1, 2019

Completion of divestment of US Synagis rights

January 25, 2019

AstraZeneca announces organisational changes

January 7, 2019

Bevespi Aerosphere approved in the EU for COPD

December 20, 2018

Lynparza meets primary endpoint in SOLO-3 trial

December 20, 2018

Phase III ROCKIES and OLYMPUS roxadustat trials

December 20, 2018

FDA approves Lynparza as 1L maintenance therapy

December 19, 2018

Update on the Phase III EAGLE trial of Imfinzi

December 7, 2018

Divestment of rights to Covis completed

December 6, 2018

Grünenthal Agreement for Nexium, Vimovo Completed

December 3, 2018

US FDA grants Fasenra ODD for EGPA

November 26, 2018

AstraZeneca provides update on Phase III MYSTIC

November 16, 2018

AstraZeneca to divest US Synagis rights to Sobi

November 13, 2018

US FDA accepts regulatory submission for Lynparza

November 12, 2018

Farxiga significantly reduced hospitalisation for

November 12, 2018

AZN: Year-to-Date and Q3 2018 Results

November 8, 2018

Divestment of rights to Covis Pharma

November 6, 2018

Additional financial information-Grünenthal deal

October 31, 2018

Grünenthal Agreement for rights to Nexium, Vimovo

October 30, 2018

AstraZeneca Extends Innate Pharma Collaboration

October 23, 2018

Lynparza shows 70% reduction in PFS ovarian cancer

October 22, 2018

CHMP positive opinion Bevespi Aerosphere

October 19, 2018

FDA Orphan Drug for Lynparza in pancreatic cancer

October 16, 2018

Atacand Agreement with Cheplapharm Completed

October 1, 2018

Previous Announcement Regarding Appointment Of NED

September 28, 2018

Overall survival data for Imfinzi: Stage III NSCLC

September 25, 2018

← Newer news releases · Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 249 decks. Every deck is listed under its year.